Coastline Trust Co Has Trimmed Shire Plc Spons Adr (SHPG) Position, Last Week AstraZeneca plc (LON:AZN) Analysts

July 12, 2017 - By Stephen Andrade

Coastline Trust Co decreased Shire Plc Spons Adr (SHPG) stake by 49.17% reported in 2016Q4 SEC filing. Coastline Trust Co sold 3,042 shares as Shire Plc Spons Adr (SHPG)’s stock rose 4.45%. The Coastline Trust Co holds 3,145 shares with $536,000 value, down from 6,187 last quarter. Shire Plc Spons Adr now has $47.37B valuation. The stock decreased 0.85% or $1.38 during the last trading session, reaching $161.91. About 200 shares traded. Shire PLC (ADR) (NASDAQ:SHPG) has risen 4.69% since July 12, 2016 and is uptrending. It has underperformed by 12.01% the S&P500.

Among 31 analysts covering AstraZeneca PLC (LON:AZN), 15 have Buy rating, 3 Sell and 13 Hold. Therefore 48% are positive. AstraZeneca PLC has GBX 7600 highest and GBX 3700 lowest target. GBX 5005.56’s average target is -2.82% below currents GBX 5151 stock price. AstraZeneca PLC had 494 analyst reports since July 23, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, April 29 by Cantor Fitzgerald. Bryan Garnier & Cie maintained AstraZeneca plc (LON:AZN) rating on Friday, October 23. Bryan Garnier & Cie has “Buy” rating and GBX 5100 target. The stock has “Buy” rating by Berenberg on Thursday, November 17. The rating was maintained by Bryan Garnier & Cie on Monday, November 16 with “Buy”. The firm earned “Market Perform” rating on Friday, December 18 by Bernstein. On Tuesday, May 2 the stock rating was maintained by HSBC with “Reduce”. The stock of AstraZeneca plc (LON:AZN) earned “Buy” rating by Jefferies on Monday, September 12. On Monday, April 25 the stock rating was maintained by Barclays Capital with “Equal Weight”. Deutsche Bank maintained the stock with “Buy” rating in Monday, February 1 report. The firm earned “Neutral” rating on Friday, July 31 by Credit Suisse. See AstraZeneca plc (LON:AZN) latest ratings:

12/07/2017 Broker: Jefferies Rating: Hold Old Target: GBX 5500.00 New Target: GBX 5300.00 Maintain
03/07/2017 Broker: Barclays Capital Rating: Overweight Old Target: GBX 6000.00 New Target: GBX 6300.00 Maintain
30/06/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 5700.00 New Target: GBX 5700.00 Maintain
23/06/2017 Broker: Morgan Stanley Rating: Overweight Old Target: GBX 5600.00 New Target: GBX 5600.00 Maintain
20/06/2017 Broker: Shore Capital Rating: Hold Maintain
19/06/2017 Broker: Credit Suisse Rating: Neutral Old Target: GBX 5000.00 New Target: GBX 5000.00 Maintain
16/06/2017 Broker: Jefferies Rating: Hold Old Target: GBX 5000.00 New Target: GBX 5500.00 Maintain
16/06/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 5700.00 New Target: GBX 5700.00 Maintain
15/06/2017 Broker: Shore Capital Rating: Hold Maintain
14/06/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 5500.00 New Target: GBX 5500.00 Maintain

AstraZeneca PLC is a biopharmaceutical company. The company has market cap of 65.36 billion GBP. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 24.71 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

About 229,583 shares traded. AstraZeneca plc (LON:AZN) has 0.00% since July 12, 2016 and is . It has underperformed by 16.70% the S&P500.